Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Labelled First Human Dose Phase 1/2a Study to Evaluate Safety, Feasibility, Efficacy of Multiple Dosing With Individualised VB10.NEO Immunotherapy in Patients With Locally Advanced or Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Clear Renal Cell Carcinoma, Urothelial Cancer or Squamous Cell Carcinoma of Head and Neck, Who Did Not Reach Complete Responses With Current Standard of Care Immune Checkpoint Blockade

Trial Profile

An Open Labelled First Human Dose Phase 1/2a Study to Evaluate Safety, Feasibility, Efficacy of Multiple Dosing With Individualised VB10.NEO Immunotherapy in Patients With Locally Advanced or Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Clear Renal Cell Carcinoma, Urothelial Cancer or Squamous Cell Carcinoma of Head and Neck, Who Did Not Reach Complete Responses With Current Standard of Care Immune Checkpoint Blockade

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs VB10-NEO (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Vaccibody
  • Most Recent Events

    • 10 Oct 2018 According to a Vaccibody media release, fist 10 patients has been enrolled in this study and vaccination is started.
    • 24 Aug 2018 According to a Vaccibody media release, company received approval from the German regulatory authority- Paul Ehrlich Institute, of an amendment to the clinical trial application (CTA) allowing for CT-guided biopsies enabling more precise assessment of deep tumors.
    • 06 Jun 2018 Planned number of patients changed from 91 to 65.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top